Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis (NCT05771675) | Clinical Trial Compass
RecruitingEarly Phase 1
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
United States90 participantsStarted 2024-10-24
Plain-language summary
The purpose of this pilot study to examine the feasibility and acceptability of simvastatin in adults with Recurrent Acute Pancreatitis (RAP) and Chronic Pancreatitis (CP).
Who can participate
Age range18 Years ā 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Provision of signed and dated informed consent form
ā. Stated willingness to comply with all study procedures and availability for the duration of the study
ā. Male or female, aged 18-75 at time of enrollment
ā. Diagnosis of Recurrent Acute or Chronic Pancreatitis not attributable to gallstones (i.e., suspected or definite biliary etiology), medications, trauma or autoimmune pancreatitis. For CP, imaging studies that can be used for diagnosis classification using Cambridge criteria46,47.
ā. Ability to take oral medication and be willing to adhere to the dosing regimen.
ā. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication.
ā. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication.
ā. No prior pancreatic surgery
Exclusion criteria
ā. Pregnancy or lactation
ā. History of autoimmune, medication caused or traumatic pancreatitis.
ā. Primary pancreatic tumors - pancreatic ductal adenocarcinoma, suspected cystic neoplasm (\>1 cm. in size or main duct involvement), neuroendocrine tumors, and other uncommon tumors.
What they're measuring
1
Examine the feasibility and acceptability of testing the effect of simvastatin on health-related quality of life outcomes in patients with recurrent acute and chronic pancreatitis.
ā. Pancreatic metastasis from other malignancies.
ā. History of solid organ transplant, HIV/AIDS.
ā. Known isolated pancreatic exocrine insufficiency (i.e.., in the absence of any eligible inclusion criteria).
ā. Subjects required to take itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, or verapamil for other clinical indications.
ā. Current simvastatin use within the past 6 months.